Aldeyra Therapeutics is a clinical-stage biotechnology enterprise dedicated to the discovery, development, and commercialization of innovative novel medicines designed to treat immune-mediated and inflammatory diseases. Its core research pipeline focuses heavily on modulating complex biological pathways—such as trapping reactive aldehyde species (RASP)—to address conditions with high unmet medical needs, including ocular inflammatory diseases like dry eye disease, systemic immune disorders, and various rare allergic or autoimmune conditions.